DESTINY-Breast03 Phase 3 Study Results

Primary Endpoint 25 25 Objective Response Rate (RANO-BM criteria) ORR (intention-to-treat population; n=15): 73.3% (95% CI 48.1-89.1) Maximum change in tumor size from baseline (%) -75 50 25 0 -100 ESMO BC 2022 #165 Mini Oral One patient with dural metastases RR (per-protocol-population; n=14): 78.6% 55 Daiichi-Sankyo

View entire presentation